KRAS and neoplasm: For instance, in patients P5 and P42, although a KRAS mutation was not detected in pretreatment samples or any subsequent peri/post-treatment samples, multiple independent variants in other genes were detected whose levels consistently correlated with tumor burden (Fig. 2b,g).